• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Catalent

Catalent beats The Street in Q1, raises revenue guidance

November 2, 2021 By Sean Whooley

Catalent

Catalent (NYSE:CTLT) shares dipped today despite first-quarter financial results that beat the consensus forecast. The Somerset, New Jersey-based company posted profits of $93 million, or 49¢ per share, on sales of $1.025 billion for the three months ended Sept. 30, 2021, for a 13.4% bottom-line gain on sales growth of 21.2%. Get the full story at […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Hydrogels, MassDevice Earnings Roundup, Wall Street Beat Tagged With: Catalent

Catalent launches $400m public offering

July 23, 2018 By Sarah Faulkner

Catalent

Catalent (NYSE:CTLT) said today that it launched a $400 million underwritten public offering of its common stock. The Somerset, N.J.-based company plans to give underwriters a 30-day option to buy up to $60 million in additional shares of common stock. Catalent, which has been on a buying spree in the last year, said it expects to use […]

Filed Under: Drug-Device Combinations, Featured, Funding Roundup, Pharmaceuticals, Wall Street Beat Tagged With: Catalent

Catalent expands early-phase development skills with $139m Juniper buyout

July 3, 2018 By Sarah Faulkner

Catalent

Catalent (NYSE:CTLT) said today that it inked a $139 million deal to acquire Juniper Pharmaceuticals (NSDQ:JNP) and its early-stage product development services. The company noted that its Juniper acquisition, set at $11.50 per share, will complement Catalent’s formulation development offerings, bioavailability solutions and clinical-scale oral dose manufacturing capabilities. “Juniper’s proven solutions and capabilities will further support […]

Filed Under: Featured, Mergers & Acquisitions, Pharmaceuticals, Research & Development, Wall Street Beat Tagged With: Catalent, juniperpharmaceuticals

Catalent reorganizes after closing Pharmica purchase

October 24, 2017 By Sarah Faulkner

Catalent

Cook Group said today that it completed the sale of Cook Pharmica to Catalent (NYSE:CTLT). Catalent announced last month that it planned to dish out $950 million to buy the biologics contract manufacturer. The newly-acquired company will be called Catalent Bloomington, according to Cook Group. “Today is an important one for the employees of Cook Pharmica […]

Filed Under: Featured, Mergers & Acquisitions, Pharmaceuticals, Wall Street Beat Tagged With: Catalent, cookpharmica

Catalent launches $450m private offering

October 10, 2017 By Sarah Faulkner

Catalent

Catalent (NYSE:CTLT) said today that its subsidiary, Catalent Pharma Solutions, plans to offer $450 million in senior unsecured notes due 2026. The private offering will be used to fund, in part, the drug-delivery company’s $950 million purchase of biologics manufacturer, Cook Pharmica. The private offering comes on the heels of an underwritten public offering that the […]

Filed Under: Drug-Device Combinations, Featured, Funding Roundup, Pharmaceuticals, Wall Street Beat Tagged With: Catalent, cookpharmica

Catalent prices offering to help fund Cook Pharmica acquisition

September 27, 2017 By Sarah Faulkner

Catalent

Catalent today priced an underwritten public offering for 6,395,000 shares of its common stock at $39.10 apiece. The offering will be used to fund, in part, the drug-delivery company’s $950 million purchase of biologics manufacturer, Cook Pharmica. In connection with the offering, Catalent granted underwriters a 30-day option to buy up to an additional 959,250 shares of […]

Filed Under: Featured, Funding Roundup, Mergers & Acquisitions, Pharmaceuticals Tagged With: Catalent, cookpharmica

Catalent floats $250m public offering to fund Cook Pharmica purchase

September 26, 2017 By Sarah Faulkner

Catalent

Catalent said today that it launched an underwritten public offering for $250 million of its common stock to fund, in part, its $950 million purchase of biologics manufacturer Cook Pharmica. In connection with the offering, Catalent is slated to grant underwriters a 3o-day option to buy up to $37.5 million of additional shares of common […]

Filed Under: Featured, Funding Roundup, Mergers & Acquisitions, Pharmaceuticals, Wall Street Beat Tagged With: Catalent, cookpharmica

Catalent dishes out $950m for biologics manufacturer

September 19, 2017 By Sarah Faulkner

Catalent

Catalent said today that it plans to purchase Cook Pharmica for $950 million in cash. Cook Pharmica, a unit of privately-held medical device maker Cook Group, is a contract manufacturer that develops biologics-based drug compounds. The deal readies Catalent for an expansion of its biologics biz. Catalent will have access to Cook Pharmica’s Indiana-based facility […]

Filed Under: Contract Services, Featured, Mergers & Acquisitions, Pharmaceuticals, Wall Street Beat Tagged With: Catalent, cookpharmica

Anika names medtech veteran as new president | Personnel Moves – July 31, 2017

July 31, 2017 By Sarah Faulkner

Anika Therapeutics

Anika Therapeutics (NSDQ:ANIK) last week named medtech veteran Joseph Darling as president, taking over the role from CEO Charles Sherwood. The chief exec plans to stay in the corner office as he transitions the role of president to Darling. Previously, Darling worked as an executive in privately-held orthopedic companies. He has also held senior level executive […]

Filed Under: Drug-Device Combinations, Featured, Personnel, Pharmaceuticals, Wall Street Beat Tagged With: AcelRx, Anika Therapeutics Inc., Catalent, mannkind, Merrimack Pharmaceuticals, oramedpharmaceuticals

Catalent, Rutgers partner to study pediatric drug formulation and delivery

July 20, 2017 By Sarah Faulkner

Catalent

The Catalent Applied Drug Delivery Institute said today that it inked a deal to work with the dept. of pharmacy practice at Rutgers University in an effort to identify and address the challenges linked to pediatric drug formulation and delivery. The collaboration plans to focus on the development and administration of medicines to children by […]

Filed Under: Featured, Pediatrics, Research & Development Tagged With: Catalent, rutgersuniversity

  • Page 1
  • Page 2
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS